MYB fusion mutations (the most common fusion NFIB) are hallmark molecular events in the development of ACC, with a mutation frequency of 16-100% (17–19), and high expression of MYB is closely related to the poor prognosis (20). This evidence concerns the gene NFIB and adrenal cortex carcinoma.